UBS Sticks to Their Buy Rating for ALS (CPBLF)

Business Insider

2 days ago

In a report released yesterday, Nathan Reilly from UBS maintained a Buy rating on ALS (CPBLF – Research Report), with a price target of A$18.50.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Reilly is ranked #1711 out of 9552 analysts.
In addition to UBS, ALS also received a Buy from J.P. Morgan's Russell Gill in a report issued on May 28. However, yesterday, Jarden maintained a Sell rating on ALS (Other OTC: CPBLF).
The company has a one-year high of $12.55 and a one-year low of $8.19. Currently, ALS has an average volume of 8,065.